Metabolic Phenotyping for Personalized Obesity Therapy

NCT ID: NCT06874270

Last Updated: 2025-03-13

Basic Information

• Recruitment Status: RECRUITING
• Total Enrollment: 80 participants
• Study Classification: OBSERVATIONAL
• Study Start Date: 2023-09-15
• Study Completion Date: 2027-09-30

Brief Summary

This study aims to develop a simple, clinically applicable method for metabolic phenotyping to personalize obesity therapy in morbidly obese individuals. The underlying concept is that the way a person's resting metabolic rate (RMR) responds to a 24-hour fast can help distinguish between two metabolic phenotypes. Individuals with a "thrifty" metabolism show a significant drop in RMR during fasting, which may make them less responsive to conventional weight loss interventions. In contrast, those with a "spendthrift" metabolism exhibit little to no drop-or even a slight increase-in RMR, suggesting they may lose weight more readily.

The trial is designed as a prospective, single-center, longitudinal cohort study involving 20 morbidly obese patients (BMI >40 kg/m²) who are already participating in a multimodal obesity therapy program. The study is divided into three phases. In the baseline phase, participants undergo comprehensive screening, which includes physical examinations, blood tests, and body composition assessments. RMR is measured using indirect calorimetry both before and after a 24-hour fasting period, and a device (Lumen™) is used to assess whether the body is primarily burning carbohydrates or fats.

After the fasting measurements, participants perform a low-protein meal test by consuming a specially calibrated chocolate beverage. Their RMR is then monitored at several time points to determine the energy required for digestion. Following this, the study moves into the very-low-calorie diet (VLCD) phase, where participants consume approximately 800 kcal per day using formula meals tailored to meet their nutritional needs despite the calorie restriction. During this 12-week phase, changes in body weight, composition, and metabolic parameters are closely monitored.

The final phase of the study is a 12-week weight maintenance period, during which the focus is on sustaining the achieved weight loss. In addition to RMR and dietary assessments, advanced techniques such as metabolomics are employed. Blood, urine, and saliva samples are collected to analyze metabolic profiles and identify potential hormonal biomarkers-such as leptin, FGF21, and adrenaline-that could further differentiate the "thrifty" and "spendthrift" phenotypes. Body composition is also assessed using methods like bioimpedance analysis (BIA), quantitative magnetic resonance imaging (qMR), and air displacement plethysmography (BodPod).

By correlating the changes in RMR with metabolic and hormonal markers, the study tests the hypothesis that individuals with a marked RMR decrease during fasting (the "thrifty" phenotype) may experience less weight loss during a hypocaloric diet compared to those with minimal RMR change (the "spendthrift" phenotype). If validated, this approach could allow clinicians to predict weight loss outcomes more accurately and tailor obesity treatments to the individual's unique metabolic profile.

Detailed Description

This study is a prospective, single-center, longitudinal cohort trial designed to unravel the metabolic heterogeneity among morbidly obese individuals and to develop a clinically feasible method for metabolic phenotyping. The aim is to identify distinct metabolic responses to a controlled fasting period that may predict weight loss outcomes and guide personalized obesity therapy.

Potential participants are morbidly obese patients (BMI >40 kg/m²) already enrolled in a multimodal obesity therapy program at the University Hospital Schleswig-Holstein, Campus Kiel. The screening process includes a thorough medical history, physical examination, and laboratory testing to exclude confounding conditions that might affect energy expenditure or the interpretation of metabolic measurements.

In the baseline phase, enrolled subjects undergo extensive assessments to characterize their metabolic status. Body composition is evaluated using several complementary techniques: bioimpedance analysis (BIA), quantitative magnetic resonance imaging (qMR), and air displacement plethysmography (BodPod). These methods provide detailed insights into fat mass, lean mass, and overall body composition. Resting metabolic rate (RMR) is measured using indirect calorimetry, with subjects placed under a canopy (haubenkalorimeter) that records oxygen consumption and carbon dioxide production to yield precise energy expenditure data.

A critical component of the study is the evaluation of RMR before and after an extended fasting period. Initially, RMR is measured following a 12-hour overnight fast. Participants then complete a 24-hour fasting period, during which continuous monitoring-via devices such as a continuous glucose monitor-ensures compliance with the fasting protocol. A second RMR measurement is taken after the fasting period, and the percentage change in RMR is calculated. Based on previous research, a significant RMR reduction (≥5.7%) classifies a subject as having a "thrifty" metabolic phenotype, while a minimal reduction or slight increase (≥+3.8%) indicates a "spendthrift" phenotype. Subjects with intermediate changes are not categorized for the primary analysis.

Following the fasting assessments, participants undergo a low-protein meal test. They consume a standardized chocolate beverage calibrated to provide 50% of their baseline RMR in caloric content. Postprandial RMR is then measured at several intervals over a three-hour period to assess the thermic effect of food and the energy cost associated with digestion. This test helps to elucidate differences in nutrient oxidation and metabolic flexibility between the two phenotypes.

After completing the baseline phase, subjects enter a 12-week very-low-calorie diet (VLCD) phase. During this period, they consume approximately 800 kcal per day through nutritionally complete formula meals that are designed to maintain a balanced macronutrient profile despite severe caloric restriction. Weight, body composition, and metabolic parameters are monitored on a weekly basis to capture the effects of the dietary intervention. The hypothesis is that individuals with a "thrifty" metabolic response may lose less weight compared to those with a "spendthrift" response, owing to their reduced energy expenditure during fasting.

Following the VLCD phase, patients transition into a 12-week weight maintenance phase. In this period, the focus shifts to sustaining weight loss and monitoring long-term metabolic changes. RMR, body composition, and dietary intake continue to be assessed periodically. Participants also use an activity tracker to document daily physical activity, ensuring that variations in energy expenditure are accounted for in the analysis.

An innovative aspect of this study is the incorporation of metabolomic analysis to identify potential biomarkers linked to the metabolic phenotypes. Biological samples-including blood, urine, and saliva-are collected at various time points throughout the study. These samples undergo metabolomic profiling using advanced techniques such as liquid chromatography-mass spectrometry (LC/MS) and nuclear magnetic resonance (NMR) spectroscopy. The goal is to identify specific metabolites or patterns-such as variations in leptin, fibroblast growth factor 21 (FGF21), and catecholamines-that correlate with the magnitude of RMR change during fasting. This analysis may reveal novel biomarkers that predict weight loss responsiveness and metabolic health.

Data collection extends beyond metabolic measurements. Participants complete visual analog scales (VAS) to assess subjective feelings of hunger and satiety, providing insights into the behavioral dimensions of appetite regulation. In addition, continuous glucose monitoring and measurements of beta-hydroxybutyrate levels are used to verify fasting compliance and to ensure the accuracy of the metabolic assessments.

The study is managed by a multidisciplinary team led by Dr. Tim Hollstein, with contributions from specialists in endocrinology, diabetology, clinical nutrition, and metabolomics. Collaborations with experts from associated institutions enhance the methodological rigor and analytical capacity of the trial. Statistical power calculations, based on prior studies, indicate that approximately 20 subjects (10 per extreme phenotype group) are required to detect significant differences in weight loss outcomes. To accommodate variability and potential dropouts, an initial screening of around 80 individuals is planned.

Safety and compliance are paramount. The protocol includes rigorous monitoring for adverse events related to fasting, blood sampling, and the use of continuous monitoring devices. Subjects who do not meet fasting criteria-confirmed via continuous glucose readings or ketone measurements-are excluded from the primary analysis but continue to receive standard obesity therapy.

Ultimately, the study seeks to bridge the gap between complex laboratory-based measurements and practical clinical applications. By establishing a reliable and straightforward method for metabolic phenotyping, it aims to enable personalized obesity treatments that are tailored to an individual's unique metabolic profile. This approach could revolutionize obesity management by providing clinicians with predictive tools to optimize weight loss interventions and improve long-term metabolic outcomes.

Conditions

Obesity and Overweight

Study Design

• Observational Model Type: COHORT
• Study Time Perspective: PROSPECTIVE

Study Groups

Extreme Thrifty

Individuals with a fasting-induced decrease of RMR \< -5.7%

No interventions assigned to this group

Extreme Spendthrift

Individuals with a fasting-induced increase of RMR \> +3.8%

No interventions assigned to this group

No extreme phenotype

Individuals with fasting-induced RMR changes greater than -5.7% and lower than +3.8%

No interventions assigned to this group

Eligibility Criteria

Inclusion Criteria

• Morbid obesity (BMI > 40 kg/m²)
• Currently undergoing a multimodal obesity therapy program at the Department of Internal Medicine I at the University Hospital Schleswig-Holstein (UKSH), Campus Kiel

Exclusion Criteria

• Type 1 or Type 2 diabetes mellitus, or fasting blood glucose >125 mg/dL, or HbA1c >6.5%
• Conditions affecting appetite or energy expenditure (e.g., Cushing's syndrome, uncontrolled hyper-/hypothyroidism, diabetes mellitus)
• Gastrointestinal diseases that may impair nutrient absorption (e.g., inflammatory bowel disease, malabsorption syndromes, peptic ulcers)
• Psychiatric disorders that influence eating behavior (e.g., active depression, anorexia nervosa, bulimia nervosa, borderline personality disorder)
• Acute, unstable cardiovascular disease requiring hospitalization within the last 6 months (e.g., stent implantation)
• Cancer requiring treatment within the past 5 years
• Chronic kidney disease at Stage IV or worse according to NKF criteria
• Active infectious disease (e.g., HIV, hepatitis)
• Active nicotine use
• Drug use (e.g., amphetamines, cocaine, heroin, marijuana)
• Regular intense physical activity (≥1 hour of sport per day)
• Non-MRI-compatible metallic implants (e.g., joint replacements, metal plates)
• Pregnancy or breastfeeding
• Use of weight-loss medications
• Clinically relevant claustrophobia
• Any other condition not specified above that, in the judgment of the investigator, could interfere with study participation or compromise patient safety

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 70 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

University Hospital Schleswig-Holstein

OTHER

Sponsor Role: lead

Responsible Party

Tim Hollstein

PD Dr. med.

Responsibility Role: PRINCIPAL_INVESTIGATOR

Locations

University Hospital Schleswig-Holstein

Kiel, Schleswig-Holstein, Germany

Site Status: RECRUITING

Countries

Germany

Central Contacts

Tim Hollstein, PD Dr. med.

Role: CONTACT

tim.hollstein@uksh.de

+4943150022000

Facility Contacts

Tim Hollstein, PD Dr. med.

Role: primary

tim.hollstein@uksh.de

+4943150022000

Other Identifiers

508000993

Identifier Type: OTHER

Identifier Source: secondary_id

D 496/21

Identifier Type: -

Identifier Source: org_study_id